Articles tagged with Cancer Cells
Ohio State University researchers have developed coatings that encourage neurons in the body to grow and connect with electrodes, boosting implant effectiveness. The coatings, which release neurotrophins over time, show promise for treating conditions such as Parkinson's disease and macular degeneration.
Researchers at UNC are developing a unique way to deliver a nucleic acid derived from bacteria to tumors, allowing the body's immune system to recognize and attack cancerous cells. The goal is to create a reliable delivery method for immunotherapy, which has shown promise but faces challenges in consistency.
A protein complex regulating primary cilia formation has been identified by NYU researchers. The complex involves three proteins: CEP290, CP110, and Rab8a, which work together to promote cilia formation on mature cells. This discovery may lead to new drug targets for diseases such as polycystic kidney disease, retinal degeneration, and...
Researchers at Rockefeller University amplify cell death signals to induce self-destruction in precancerous cells. By inactivating a protein called IAP, they found that mice without the RING domain lived twice as long as those with it, highlighting a potential breakthrough in cancer therapy.
Researchers at the University of Texas Medical Branch have found that shutting down gastrin-releasing peptide receptors can dramatically suppress neuroblastoma tumor formation and slow its spread. This breakthrough could lead to the development of new therapies for this devastating disease.
Researchers have developed irreversible electroporation (IRE), a minimally invasive technique that uses electric pulses to destroy cancer tissue without heat. The technology has shown promising results in laboratory testing and preclinical mouse models, with complete regression achieved in 92% of treated tumors.
Researchers use ruthenium as a catalyst to increase oxidant levels in infected cells, ultimately destroying cancerous cells. The study offers a promising alternative to traditional cancer treatments, which often adapt quickly to targeted drugs.
Researchers discuss the difficulties in diagnosing and treating Barrett's oesophagus, a pre-cancerous condition often associated with chronic acid reflux. The authors suggest improving detection and treatment by developing standardized indicators, less costly screening methods, and laboratory animal models.
The Scripps Research Institute team has identified a protein called Nrm1 that plays a crucial role in regulating the cell cycle. When DNA replication stalls, Nrm1's repression of certain genes is blocked, allowing those genes to be expressed again, which enables the production of proteins needed to correct the problem.
Researchers develop powerful tool for investigating gene function using siRNA and lentiviral vectors. The method enables long-term down-regulation of specific target genes in various cell types, facilitating cancer cell biology studies.
Researchers have discovered that methadone has surprising killing power against leukemia cells, including those resistant to chemotherapy and radiation. The agent activates the mitochondrial pathway, inducing apoptosis in cancer cells without harming non-leukemic blood cells.
A new study reveals that dividing cells exhibit an unprecedented level of regulation, with over 1,000 proteins becoming highly phosphorylated. This discovery has significant implications for understanding cell cycle disorders and developing therapeutic targets.
Scientists at NYU Langone Medical Center have identified a new cellular pathway that responds to DNA damage and is linked to the development of cancer. The pathway involves a process that targets proteins for disposal, which could potentially be used to sensitize cancer cells to treatment.
Scientists are using cyanobacteria and plant materials to identify anticancer lead compounds that may be more effective than current treatments. The goal is to develop naturally occurring substances that target key cellular targets such as the proteasome and histone deacetylase.
Researchers have developed a novel therapy that utilizes magnetic nanoparticles to target and capture cancer cells, which can then be removed from the body. This technology shows promise in treating ovarian cancer, where free-floating cancer cells spread throughout the abdominal cavity.
Researchers at DKFZ have developed a new simulation method to predict the molecular targets that control cell behavior. This breakthrough may lead to new treatments against cancer metastasis by targeting specific genetic changes.
Researchers at UGA's Franklin College of Arts and Sciences have identified a mechanism that explains how telomerase enzymes are recruited to chromosome ends in cancer cells. The study highlights the potential for targeting telomerase as a means to stop cancers from spreading, providing new avenues for investigation into cancer growth.
Research by VIB-K.U.Leuven scientists finds that location in cell affects carcinogenicity of NUP214-ABL1 protein, a kinase linked to T-cell acute lymphoblastic leukemia. This discovery opens new avenues for targeted therapies and potential treatment approaches.
Scientists at the University of Pennsylvania School of Medicine found that myosin-I motors sense minute changes in force to regulate cellular processes. This discovery has implications for understanding hearing, balance, glucose uptake, and more.
Researchers at Washington University School of Medicine discovered a single protein, HS1, that enables key functions of natural killer (NK) cells. The protein allows NK cells to pursue targets, latch on, and kill them. Further study of HS1 may open new possibilities for revving up NK cells to fight infections and cancer.
Scientists have discovered a chemical mechanism by which argyrin destroys tumours and prevents protein breakdown, leading to reduced tumour growth and no side effects. Researchers are now working to optimize the molecule for clinical testing in the near future.
A new study reveals that mantle cell lymphoma incidence is increasing, especially among men and Caucasians, with advanced stages detected in nearly 75% of patients. The research also highlights the need for better understanding of the disease's epidemiology and development of novel treatment agents.
A study by UT Southwestern Medical Center reveals that the protein TCF7L2 actually suppresses the growth of human cancer cells in culture, contrary to its previous role in promoting colorectal cancer. This groundbreaking finding opens new avenues for understanding and treating colorectal cancer.
Scientists discovered a compound, STF-62247, that induces autophagy in VHL-deficient kidney cancer cells, leading to selective cell death. This finding represents a new direction for targeted therapy against kidney cancer.
Researchers have identified a novel activity, called mitotic checkpoint factor 2 (MCF2), that prevents cells from dividing with improperly separated chromosomes. This finding may help increase the efficiency of cancer drugs and improve our understanding of mitosis.
A University of Texas at Austin biomedical engineer has received a $1.5 million grant to develop molecular imaging technologies for cancer screening, diagnosis, and therapy using nanoparticles. The project aims to detect and treat cancer at the cellular level, targeting cancer cells while sparing healthy tissue.
Researchers discovered how filopodia extensions are generated and integrated with lamellipodia/ruffles in human cancer cells. The study reveals a complex interplay between these actin-based structures, suggesting that suppression of filopodia is needed for efficient cell migration.
Researchers use monoclonal antibodies attached to carbon nanotubes that heat up when exposed to near-infrared light, killing cancer cells. The technique shows promise for targeting specific sites on lymphoma cells and potentially delivering a deadly payload.
Researchers developed a computer-based method called CoMet to analyze cellular activity and predict anti-tumor activity of metabolites. The tool identified nine metabolites that exhibit anticancer properties when added to leukemia cells.
Researchers at Tufts University have found that Smad proteins control the processing of a subset of microRNA, including miR-21. This discovery reveals a new role of Smad proteins in regulating microRNA processing, which is a contributing factor in cardiovascular disorders and cancer.
A Phase 2 clinical trial of GCS-100, a polysaccharide targeting galectin-3, demonstrates apoptosis induction and reduced leukocyte counts in relapsed CLL patients. The treatment was generally well tolerated with mild-to-moderate adverse events.
Researchers have developed artificial viruses that can transport genes and drugs into cancer cells, eliminating immune responses and potential side effects. The viruses are self-assembled using a ribbon-like protein structure, allowing for precise control over their size and shape.
Researchers at Duke University Medical Center have identified a subset of immune system B cells that can regulate inflammation. These regulatory B cells, called B10 cells, produce a potent cytokine that inhibits immune responses. Depleting or enhancing these cells may lead to new treatments for autoimmune diseases and cancer.
UT Southwestern faculty members Dr. Lora Hooper, Dr. Youxing Jiang, and Dr. Hongtao Yu were named as Howard Hughes Medical Institute investigators for their outstanding biomedical research. The HHMI appointment brings the total number of UT SWM faculty members to 13.
Delft University of Technology researchers have observed the spontaneous repair of DNA damage in real time, revealing a key mechanism for repairing breaks. This insight is crucial as errors in this process can lead to cancerous cell development.
Researchers at Goethe University Frankfurt have discovered two gatekeeper proteins, Rpn13 and an ubiquitin receptor, on the proteasome. This finding has significant implications for cancer research, as it may lead to the development of targeted drugs that can block protein breakdown and prevent tumor cell proliferation.
GAL-3 stimulates pancreatic stellate cell activation, which promotes the proliferation and invasion of pancreatic cancer cells. This interaction provides a new therapeutic target for controlling pancreatic cancer.
A new test using galectin-3 may help identify benign thyroid nodules, reducing the need for surgery. The test showed high sensitivity and specificity, with a positive predictive value of 82%.
Researchers have developed a novel method to expand natural killer cells from umbilical cord blood, effectively killing human leukemia cells in mice. The treatment demonstrates significant cytotoxic activity against both acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML).
A new biosensor measures the oxidation state of glutathione, an important protection molecule, to detect cellular stress. The sensor is highly sensitive and precise, allowing researchers to track short-term variations in oxidative processes.
Researchers discovered a drug combination that inhibits glycolysis and intensifies cellular starvation, resulting in over 90% cell death in human tissue cultures of acute lymphocytic leukemia. The novel approach offers a promising alternative to current treatments.
A team of researchers led by University of Saskatchewan microbiologist Wei Xiao has found a way to trigger a protein combination that sends an SOS signal for cells to fight cancer-causing agents. The discovery could lead to better cancer diagnosis and potentially pave the way for a new type of drug.
A study reveals that immune killer T cells induce cell death by disrupting mitochondria in two distinct ways, targeting enzymes and reactive oxygen production. This understanding provides a new insight into the major T cell defense pathway against viral infections and cancer.
Researchers found that vitamin D increases expression of a key enzyme, protecting prostate cells from damage and injuries leading to cancer. Vitamin D also reduces reactive oxygen species, which can damage DNA and play a role in aging or causing cancer.
Researchers at Melbourne's Walter and Eliza Hall Institute have discovered a key step in the 'puncture' mechanism of cell death, which drives apoptosis. The discovery has important implications for the development of drugs that can regulate cell death, with potential applications in cancer and degenerative disease treatments.
The Nix protein plays a crucial role in the maturation of red blood cells by facilitating autophagy, a process that removes damaged organelles like mitochondria. This regulation is essential for maintaining cellular quality and preventing anemia.
Researchers found higher levels of beta-catenin, a protein involved in cell signaling and development, in the brains of chronic alcoholics. The protein may play a role in the reward circuitry, suggesting a potential treatment target for alcohol dependence.
Researchers found that tumor cells can become resistant to radiation by jamming their self-destruct mechanisms, which could lead to improved cancer treatments. The study suggests that controlling the blocking-unblocking mechanism of DNA sequences involved in cell death may be key to making cancer cells sensitive to radiation again.
Research found that herbal extracts from Phyllanthus emblica and Terminalia bellerica exhibit synergistic growth inhibitory effects when combined with conventional cytotoxic agents like doxorubicin and cisplatin. This enhances therapeutic efficacy while minimizing side effects, offering a potential new approach to cancer treatment.
Scientists have determined the crystal structures of two DNA-repair proteins, AlkB and ABH2, which repair alkylation damage to DNA. This discovery could lead to designing molecules that interfere with the repair process, making cancer treatment more effective.
Researchers at Cold Spring Harbor Laboratory have discovered a biochemical pathway where adenoviral protein E1A binds to p400, stabilizing Myc, a key oncoprotein. This interaction can lead to the promotion of cancer cell growth and tumorigenesis.
Researchers at Yale University have discovered a new drug compound, NV-128, that can induce the death of ovarian cancer cells resistant to chemotherapy. The compound works by halting the activation of the mTOR protein pathway, which is associated with tumor growth and resistance to conventional therapies.
Researchers have found that cancer cells use glucose to avoid programmed cell death and maintain survival through the protein Akt. By exploiting this mechanism, cancer cells can bypass normal safeguards and continue to grow even without growth factors.
Researchers present promising results for new therapies targeting VEGF receptors and blood vessel formation in various types of cancer. These treatments have shown potential to shrink tumors and prolong survival for patients with glioblastoma and rectal cancer.
Researchers have discovered novel methods for delivering drugs directly to cancer tumors, including the use of peptides and nanotechnology. These methods show promise in reducing malignant tumors in mice and increasing survival rates.
A University of Central Florida scientist has secured $1 million in NIH funding to research the death protein, BAX, which could lead to breakthroughs in treating cancer and heart disease. By understanding how BAX triggers cell death, she hopes to develop a peptide-based therapeutic approach to stimulate or protect healthy cells.
Scientists at Northwestern University successfully blocked the communication between inflammatory cells and prostate cancer cells, reducing their invasive activity. The findings suggest using existing anti-inflammatory drugs to control cancer spread and metastasis.
Researchers observed a group of six enzymes forming a cluster in living cells, which are essential for cell replication and DNA production. This discovery could lead to new cancer treatments by disrupting purine synthesis and halting cancer cell replication.
Researchers at USC have found that fasting for two days protects healthy cells from chemotherapy, while leaving cancer cells vulnerable. This discovery holds promise for developing more selective and less toxic chemotherapy treatments.
Researchers found that microRNA miR-200 is a consistent marker of cancer cells expressing E-cadherin but lacking Vimentin. Altering miR-200 levels induced changes consistent with either inducing EMT or the reverse process.